Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933916 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL30424119 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL860766 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5071832 | 0.82 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL8934224 | 0.78 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL8934166 | 0.77 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL8937611 | 0.77 | PTGS2 (0.71) | PTGS2PTGS1F10 | |
| SCHEMBL8933879 | 0.76 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL8933882 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8933845 | 0.71 | PTGS2 (0.74) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-7402603-B2 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7345088-B2 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | PENN STATE RESEARCH FOUNDATION (US) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885F2 2511/4885 |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885F2 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.